Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?

This publication has 22 references indexed in Scilit:

• Mechanistic Differences of Various AT ₁ -Receptor Blockers in Isolated Vessels of Different Origin
  Hypertension, 1999
• The Antihypertensive Effect and Tolerability of Candesartan Cilexetil, a New Generation Angiotensin II Antagonist, in Comparison with Losartan
  Blood Pressure, 1998
• Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
  European Journal of Clinical Pharmacology, 1997
• The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
  Clinical Therapeutics, 1996
• Losartan Potassium
  Drugs, 1996
• Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension
  Journal Of Hypertension, 1995
• Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT₁‐receptor subtype
  British Journal of Pharmacology, 1993
• Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
  British Journal of Pharmacology, 1993
• Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist
  Biochemical Pharmacology, 1993
• Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease
  The American Journal of Medicine, 1972